Fat distribution, HbA1c and hypoglycaemia in overweight and obese patients with type 2 diabetes: a comparison of NPH and insulin detemir from a pilot randomised clinical trial

被引：0

作者：

Tinahones, F. J. ^{[1
]}

Gomez-Huelgas, R. ^{[2
]}

Garcia-Alegria, J. ^{[3
]}

Tapia-Guerrero, M.

Martos-Perez, F. ^{[4
]}

机构：

[1] Hosp Virgen de la Victoria, Malaga, Spain

[2] Hosp Carlos Hayer, Dept Internal Med, Malaga, Spain

[3] Hosp Costa del Sol, Marbella, Spain

[4] Hosp Alta Resoluc, Benalmadena, Spain

来源：

DIABETOLOGIA | 2011年 / 54卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

671

引用

页码：S273 / S273

页数：1

共 50 条

[1] Insulin detemir reduces hypoglycemic risk at comparable HbA1c values compared to NPH in patients with type 1 diabetes
Heller, S
Kim, H
DIABETES, 2005, 54 : A120 - A120
[2] Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes
Jones, DR
Kim, H
Heller, S
Clauson, P
DIABETOLOGIA, 2005, 48 : A92 - A93
[3] More subjects achieve an HbA1c ≤7% without hypoglycaemia or weight gain when treated with insulin detemir in comparison with NPH insulin
Hermansen, K.
Larsen, J.
Tamer, S. C.
Mathieu, C.
DIABETOLOGIA, 2007, 50 : S412 - S412
[4] Maternal glycaemic control and hypoglycaemia in pregnancy: a randomised trial comparing insulin detemir with NPH insulin in 310 subjects with type 1 diabetes
Mathiesen, E. R.
Damm, P.
Hod, M.
McCance, D. R.
Ivanisevic, M.
Garcia, S.
Jovanovic, L.
DIABETOLOGIA, 2011, 54 : S486 - S487
[5] The Effect of Insulin Detemir on Fat Distribution and Weight Parameters in Overweight and Obese Subjects with Type 2 Diabetes
Tinahones, Francisco J.
Gomez-Huelgas, Ricardo
Garcia-Alegria, Javier
Tapia-Guerrero, Maria J.
Martos Perez, Francisco
DIABETES, 2011, 60 : A309 - A309
[6] Insulin detemir incurs a lower risk of hypoglycaemia than NPH insulin for any level of HbA1c when added to oral agents in a treat-to-target protocol for patients with type 2 diabetes
Kolendorf, K
Kim, H
Clauson, P
DIABETOLOGIA, 2005, 48 : A302 - A303
[7] Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients -: The PREDICTIVE™ BMI clinical trial
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
DIABETIC MEDICINE, 2008, 25 (08) : 916 - 923
[8] Efficacy and safety of empagliflozin in younger overweight/obese patients with Type 2 diabetes with HbA1c ≥8%
Merker, L.
Lund, S. S.
Hantel, S.
Salsali, A.
Kim, G.
Broedl, U. C.
Woerle, H. J.
Hach, T.
DIABETIC MEDICINE, 2015, 32 : 90 - 90
[9] Lower rate of hypoglycaemia but comparable glycaemic control with insulin detemir compared to NPH insulin in patients with type 1 diabetes
Hermansen, K.
Heller, S.
Andersen, M.
Russell-Jones, D. L.
DIABETOLOGIA, 2009, 52 : S359 - S359
[10] Once-daily dosing of insulin detemir is associated with lower risk of hypoglycaemia at similar levels of HbA1c compared to once-daily NPH insulin in subjects with type 1 diabetes mellitus
Shaw, J. E.
Larsen, J.
Pedersen, C. B.
Tang-Fui, S.
DIABETOLOGIA, 2008, 51 : S391 - S391

← 1 2 3 4 5 →